Ethylene

Ethylene

SCHEMBL6992896

C=C.CCOC(C)OCC.COc1cccc2c1C(=O)CN(CCCN1CCC(C(=O)c3ccc(F)cc3)CC1)S2(=O)=O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.44
CYP2C19 P33261 1/20 0.44
HTR2A P28223 3/20 0.43
DRD2 P14416 1/20 0.43
HTR2C P28335 1/20 0.43
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
UBE2N P61088 1/20 0.41
GRM2 Q14416 1/20 0.40
HSD11B1 P28845 2/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7107482 0.92 CYP2D6 (0.51) CYP2D6CYP2C19HTR2ADRD2HTR2C
Ethylene SCHEMBL6995181 0.86 DRD2 (0.43) HTR2ADRD2HTR2CKDM4EKMT2A
Ethylene SCHEMBL6995216 0.85 DRD2 (0.51) HTR2ADRD2HTR2CHSD11B1LMNA
Ethylene SCHEMBL6994271 0.85 DRD2 (0.49) HTR2ADRD2HTR2CHSD11B1LMNA
Ethylene SCHEMBL6997038 0.84 HTR7 (0.42) HTR2ADRD2HTR2CKMT2AMEN1
Ethylene SCHEMBL6996889 0.82 DRD2 (0.41) CYP2D6HTR2ADRD2HTR2CKDM4E
Ethylene SCHEMBL6990074 0.82 DRD2 (0.41) CYP2D6HTR2ADRD2HTR2CKDM4E
SCHEMBL7104893 0.82 CYP2D6 (0.49) CYP2D6CYP2C19HTR2AHTR2CKDM4E
SCHEMBL7104889 0.82 CYP2D6 (0.49) CYP2D6CYP2C19HTR2AHTR2CKDM4E
Ethylene SCHEMBL6997843 0.81 DRD2 (0.44) CYP2C19HTR2ADRD2KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6664251-B2 Serotonin receptor antagonist; treating cardiovascular disorder DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-12-16 US disclosed
US-20030078256-A1 Benzothiazine derivative SUNTORY LIMITED (JP) 2003-04-24 US disclosed
EP-0749967-B1 Substituted benzothiazine derivative SUNTORY LTD (JP) 2003-01-22 EP disclosed
US-6316442-B1 TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES SUNTORY LIMITED (JP) 2001-11-13 US disclosed
US-6001827-A Benzothiazine derivative SUNTORY LIMITED (JP) 1999-12-14 US disclosed
EP-0749967-A1 Substituted benzothiazine derivative SUNTORY LIMITED (JP) 1996-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078256-A1 Benzothiazine derivative TPH2, ADRB2, TPH1 CYP2D6 705/4885CYP2C19 1202/4885HTR2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.